checkAd

     139  0 Kommentare Targovax's ONCOS-102 mesothelioma 24-month data shows class-leading median overall survival - Seite 3

    [1] 1 Vogelzang 2003, Ceresoli 2006, Zalcman 2015, Tsao 2019, Scagliotti 2019, Baas 2020 SITC 2020 poster

    For further information, please contact:

    Øystein Soug, CEO
    Phone: +47 906 56 525
    Email: oystein.soug@targovax.com

    Renate Birkeli, Investor Relations
    Phone: +47 922 61 624
    Email: renate.birkeli@targovax.com

    Media enquires:

    Andreas Tinglum - Corporate Communications (Norway)
    Phone: +47 9300 1773
    Email: andreas.tinglum@corpcom.no

    IR enquires:

    Lesen Sie auch

    Kim Sutton Golodetz - LHA Investor Relations (US)
    Email: kgolodetz@lhai.com
    Phone: +1 212-838-3777

    This information was brought to you by Cision http://news.cision.com

    https://news.cision.com/targovax/r/targovax-s-oncos-102-mesothelioma-24-month-data-shows-class-leading-median-overall-survival,c3364714

    The following files are available for download:

    https://mb.cision.com/Public/17093/3364714/b95e6ec6e1a750da.pdf

    press this link

     

    Seite 3 von 3



    PR Newswire (engl.)
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Verfasst von PR Newswire (engl.)
    Targovax's ONCOS-102 mesothelioma 24-month data shows class-leading median overall survival - Seite 3 - Median overall survival (mOS) for first-line treatment with ONCOS-102 plus chemotherapy will be between 21.9 and 25.0 months, compared with mOS of 13.5 months in the chemotherapy-only control group - Broad and powerful immune activation pattern …